Dr. Perry D. Nisen
Independent Director
With extensive experience in medical research and development and management positions in leading pharmaceutical companies, Dr. Nisen provides a unique perspective on business and R&D activities.
Dr. Nisen joined the Board of Directors in 2017.
In July 2021, he became Chief Executive Officer of Quanta Therapeutics Inc., a privately held biotechnology company.
In 2018, he joined Soffinova Investments as Executive Partner, Private Equity and transitioned in January 2021 to a consultant role.
From 2014 to 2017, Dr. Nisen served as Chief Executive Officer and the Donald Bren Chief Executive Chair of Sanford Burnham Prebys Medical Discovery Institute.
From 2004 to 2014, Dr. Nisen held various roles at GlaxoSmithKline, most recently as Senior Vice President, Science and Innovation.
From 1997 to 2004, Dr. Nisen served as Divisional Vice President, Global Oncology Development, and as Divisional Vice President, Cancer Research, at Abbott Laboratories. Previously, he was the Lowe Foundation Professor of Neuro-Oncology at the University of Texas Southwestern Medical Center.
From 2016 to 2017, Dr. Nisen served as a director of Mirna Therapeutics, Inc.
He received a B.S. from Stanford University, a Master’s degree in molecular biology, and an M.D. and PhD from Albert Einstein College of Medicine.
Dr. Nisen serves as Chair of our Science and Technology Committee and member of our Compliance and Human Resources and Compensation Committees.
Dr. Sol J. Barer
Chairman of the Board Independent Director
Richard Francis
President and Chief Executive Officer, Member of the Board of Directors
Rosemary A. Crane
Independent Director
Amir Elstein
Independent Director
Chen Lichtenstein
Independent Director
Gerald M. Lieberman
Independent Director
Roberto A. Mignone
Independent Director
Prof. Ronit Satchi-Fainaro
Independent Director
Prof. Varda Shalev
Independent Director
Janet S. Vergis
Independent Director
Dr. Tal Zaks
Independent Director
